OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 100,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was acquired at an average cost of $1.59 per share, with a total value of $159,000.00. Following the transaction, the chief executive officer now owns 211,712,405 shares of the company’s stock, valued at $336,622,723.95. This trade represents a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The shares were purchased at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

OPK stock opened at $1.58 on Friday. OPKO Health, Inc. has a twelve month low of $0.85 and a twelve month high of $1.75. The business’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.44. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Institutional Investors Weigh In On OPKO Health

Institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC bought a new position in OPKO Health in the 1st quarter worth approximately $258,000. Price T Rowe Associates Inc. MD raised its position in OPKO Health by 4.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after purchasing an additional 17,671 shares during the last quarter. AWM Investment Company Inc. raised its position in OPKO Health by 18.2% in the 1st quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock worth $1,560,000 after purchasing an additional 200,000 shares during the last quarter. Tidal Investments LLC bought a new position in OPKO Health in the 1st quarter worth approximately $239,000. Finally, Comerica Bank raised its position in OPKO Health by 125.0% in the 1st quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 50,000 shares during the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

OPK has been the subject of a number of research reports. Piper Sandler reissued an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Thursday, September 26th. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th. Finally, StockNews.com upgraded OPKO Health to a “sell” rating in a report on Saturday, July 27th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.